QRS Diagnostic/Sunlight Medical team up:
This article was originally published in Clinica
Executive Summary
Two high-tech device firms have teamed up to adapt their software so that their tools can be integrated. Plymouth, Minnesota-based QRS Diagnostic's computer cards, SpiroCard and EKGCard, can now been used on Tel Aviv, Israel-based Sunlight's Omnisense bone sonometry units. EKGCard turns standard computing devices into portable ECG heart monitors, while SpiroCard is a software-based spirometer with disposable mouthpieces. "Adding these applications to Omnisense costs up to 50% less than purchasing separate heart monitors and spirometers," said Sunlight's general manager for Europe, Yfat Scialom. Sunlight markets QRS's PC card devices in Europe and Asia as Omnisense EKGCard and Omnisense SpiroCard.
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.